Adragos Pharma, a global pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Munich, ...

Tomorrows, a global health technology company connecting patients and physicians with all possible pre-approval treatment options, today announced the launch of its next-generation AI platform.

Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 SOUTH SAN FRANSCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdi ...

Inc. (NYSE American: PTN) has announced the completion of their Phase 2 clinical trial for an obesity treatment, marking a ...

Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.

Patient enrollment is expected to begin in the first half of 2025, subject to final protocol review by regulatory authorities ...

While some information has been restored, scientists are still alarmed over the removal of data. It's not clear what has ...

February 6, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that the first subject has ...

Northwestern Medicine is a global leader in clinical trial research, including spine CLARITY is a randomized study designed ...

Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the ...

The FDA’s approval for expanded use reinforces LP-310’s potential as a new therapeutic option for OLP and supports ongoing clinical development efforts.